Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis
B Ramos-Molina, J Rossell… - Frontiers in …, 2024 - frontiersin.org
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), a
leading cause of chronic liver disease, has increased worldwide along with the epidemics of …
leading cause of chronic liver disease, has increased worldwide along with the epidemics of …
Exploring Biomarkers in Nonalcoholic Fatty Liver Disease Among Individuals With Type 2 Diabetes Mellitus
F Ahmadizar, ZM Younossi - Journal of Clinical Gastroenterology, 2024 - journals.lww.com
Integrating biomarkers into a comprehensive strategy is crucial for precise patient
management, especially considering the significant healthcare costs associated with …
management, especially considering the significant healthcare costs associated with …
[HTML][HTML] The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies
P Jiang, Y Zeng, W Yang, L Li, L Zhou, L Xiao… - Biomedicine & …, 2024 - Elsevier
Abstract Background Glucagon-like peptide-1 (GLP-1)/glucagon (GCG) dual receptor
agonists with different receptor selectivity are under investigation and have shown …
agonists with different receptor selectivity are under investigation and have shown …
[PDF][PDF] Longitudinal study of the development of Non-Alcoholic Fatty Liver disease (NAFLD). Key events and biomarker search.
MM GRAU - roderic.uv.es
Quería darles las gracias a todas las personas importantes para mí en estos últimos años,
aquellas que han permanecido a mi lado, apoyándome, ayudándome y dándome ánimos …
aquellas que han permanecido a mi lado, apoyándome, ayudándome y dándome ánimos …